This guideline will therefore provide advice and rationale for health professionals in making choices and decisions in the management of this disease.
BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics
These guidelines provide evidence-based guidance for UK clinicians prescribing biologics for adult patients with axSpA. This includes the criteria for starting treatment, the choice of drug and assessing response to treatment.
BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs
The purpose of this guideline is to provide up-to-date, evidence-based recommendations for the safe use of non-biologic DMARDs in adults (>16 years old).
This guideline aims to offer revised and updated, concise, patient-focused, evidence-based, expert recommendations for the management of gout in the UK.
The British Society for Rheumatology guideline for the management of adults with primary Sjögren’s Syndrome
This document aims to provide a pragmatic, practical guideline for the management of adults with pSS.
The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults
The aim of this guideline was to produce recommendations for the management of adult lupus patients in the UK that cover the diagnosis, assessment and monitoring of lupus and the treatment of mild, moderate and severe active lupus disease...
Venous thromboembolism (VTE) and bleeding are serious complications of cancer and its treatment. A recent survey of UK paediatric haematologists and oncologists identified a broad variety of practice in the management of issues...
The role of imaging in myeloma has gained increasing importance over the past few years. The recently revised definition of myeloma from the International Myeloma Working Group (IMWG) includes cross sectional imaging...
Guidelines for screening and management of late and long-term consequences of myeloma and its treatment
A growing population of long-term survivors of myeloma isnow accumulating the ‘late effects’ not only of myeloma itself, but also of several lines of treatment given throughout the course of the disease.
The objective of this guideline is to provide healthcare professionals with guidance on the management of patients with primary autoimmune haemolytic anaemia (AIHA).